• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oragenics Inc. Common Stock (NY:OGEN)

0.6200 -0.0190 (-2.97%)
Official Closing Price Updated: 8:00 PM EDT, May 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 27,032
Open 0.6472
Bid (Size) 0.6200 (200)
Ask (Size) 0.7700 (100)
Prev. Close 0.6390
Today's Range 0.6200 - 0.6472
52wk Range 0.5038 - 9.600
Shares Outstanding 4,168,223
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Advances Phase IIa Trial Enrollment For Concussion Treatment Candidate
May 05, 2026
Via Investor Brand Network
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Reports Early Dosing Progress in Phase IIa Trial of Intranasal Concussion Therapy
April 20, 2026
Via Investor Brand Network

Performance

YTD
-25.7%
-25.7%
1 Month
+6.0%
+6.0%
3 Month
-20.5%
-20.5%
6 Month
-45.1%
-45.1%
1 Year
-87.8%
-87.8%

More News

Read More
BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Doses First Patient in Phase IIa Trial of Concussion Treatment
April 13, 2026
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Reports Going Concern Audit Opinion Disclosure
March 26, 2026
Via Investor Brand Network
TinyGemsBreaks – Oragenics Inc. (NYSE American: OGEN) Files 2025 Form 10-K And Provides Operational Update
March 17, 2026
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Initiates First Clinical Site for Phase IIa Trial of ONP-002 in Australia
March 12, 2026
Via Investor Brand Network
BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Explores CNS Asset Acquisitions To Expand Brain Health Pipeline
March 11, 2026
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Receives Australian Ethics Approval to Launch Phase IIa Concussion Trial
March 10, 2026
Via Investor Brand Network
BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Previews 2026 Milestones for Intranasal Concussion Therapeutic ONP-002
February 09, 2026
Via Investor Brand Network
BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Engages DUCK FLATS Pharma for IND Readiness and Regulatory Execution
February 03, 2026
Via Investor Brand Network
BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Participates in SCOPE Summit 2026 Ahead of Phase 2a Concussion Trial
February 02, 2026
Via Investor Brand Network
BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) to Present at Sequire Investor Summit 2026
January 14, 2026
Via Investor Brand Network
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Regains NYSE Compliance, Advances Toward First Clinical Trial and Expands AI-Driven Neurology Pipeline
November 12, 2025
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Oragenics Q3 2025 Shareholder Update
November 12, 2025
From Oragenics, Inc.
Via Business Wire
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Regains NYSE Compliance, Strengthens Balance Sheet for Clinical Advancement
October 21, 2025
Via Investor Brand Network
News headline image
Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
October 21, 2025
From Oragenics, Inc.
Via Business Wire
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Partners with Receptor.AI to Accelerate AI-Driven Discovery of Brain-Targeted Therapeutics
October 07, 2025
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development
October 07, 2025
From Oragenics
Via Business Wire
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Highlights Q2 2025 Progress and Prepares for Phase IIa Concussion Trial
August 11, 2025
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Selects Southern Star Research as CRO for Phase IIa Trial of Intranasal Concussion Therapy ONP-002
July 31, 2025
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Secures U.S. Manufacturing Partner Ahead of Phase IIb Trials for Concussion Drug
July 16, 2025
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
July 07, 2025
Via Benzinga
News headline image
Monday's after hours session: top gainers and losers ↗
July 07, 2025
Via Chartmill
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Secures $16.5 Million in Preferred Stock Offering to Advance Intranasal Concussion Therapy
July 03, 2025
Via Investor Brand Network
News headline image
Get insights into the top gainers and losers of Wednesday's after-hours session. ↗
July 02, 2025
Via Chartmill

Frequently Asked Questions

Is Oragenics Inc. Common Stock publicly traded?
Yes, Oragenics Inc. Common Stock is publicly traded.
What exchange does Oragenics Inc. Common Stock trade on?
Oragenics Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Oragenics Inc. Common Stock?
The ticker symbol for Oragenics Inc. Common Stock is OGEN on the New York Stock Exchange
What is the current price of Oragenics Inc. Common Stock?
The current price of Oragenics Inc. Common Stock is 0.6200
When was Oragenics Inc. Common Stock last traded?
The last trade of Oragenics Inc. Common Stock was at 05/06/26 08:00 PM ET
What is the market capitalization of Oragenics Inc. Common Stock?
The market capitalization of Oragenics Inc. Common Stock is 2.58M
How many shares of Oragenics Inc. Common Stock are outstanding?
Oragenics Inc. Common Stock has 3M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap